Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Synovial IL-17A+ CD8+ T cells display a polyfunctional, pro-inflammatory and tissue-resident memory phenotype and function in psoriatic arthritis.

Steel KJA, Srenathan U, Ridley M, Durham LE, Wu SY, Ryan SE, Hughes CD, Chan E, Kirkham BW, Taams LS.

Arthritis Rheumatol. 2019 Nov 2. doi: 10.1002/art.41156. [Epub ahead of print]

PMID:
31677365
2.

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.

Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, Zhu B, de la Torre I, De Leonardis F, Taylor PC.

J Clin Med. 2019 Sep 5;8(9). pii: E1394. doi: 10.3390/jcm8091394.

3.

Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.

Clunie G, McInnes IB, Barkham N, Marzo-Ortega H, Patel Y, Gough A, Packham J, Kyle S, Kirkham B, Sheeran T, Coope H, Bishop-Bailey A, McHugh N.

Rheumatol Adv Pract. 2018 Oct 17;2(2):rky042. doi: 10.1093/rap/rky042. eCollection 2018.

4.

Assessment of Age-related Oxygenation Changes in Calf Skeletal Muscle by Photoacoustic Imaging: A Potential Tool for Peripheral Arterial Disease.

Kirkham BM, Schultz SM, Ashi K, Sehgal CM.

Ultrason Imaging. 2019 Sep;41(5):290-300. doi: 10.1177/0161734619862287. Epub 2019 Jul 19.

PMID:
31322030
5.

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R.

Ann Rheum Dis. 2019 Sep;78(9):1167-1178. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5. Review.

6.

Best-practice Indicators in Psoriatic Disease Care.

Helliwell PS, Favier G, Gladman DD, Soriano ER, Kirkham BW, Coates LC, Puig L, Boehncke WH, Thaçi D.

J Rheumatol Suppl. 2019 Jun;95:38-45. doi: 10.3899/jrheum.190120.

PMID:
31154403
7.

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.

Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, Pink AE.

Br J Dermatol. 2019 Nov;181(5):1068-1070. doi: 10.1111/bjd.18031. Epub 2019 Jul 18. No abstract available.

PMID:
31017658
8.

Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis.

Gullick NJ, Ibrahim F, Scott IC, Vincent A, Cope AP, Garrood T, Panayi GS, Scott DL, Kirkham BW; TITRATE Programme Investigators.

BMC Rheumatol. 2019 Feb 25;3:6. doi: 10.1186/s41927-019-0054-y. eCollection 2019.

9.

The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.

Scott IC, Ibrahim F, Panayi G, Cope AP, Garrood T, Vincent A, Scott DL, Kirkham B; TITRATE Programme Investigators.

Semin Arthritis Rheum. 2019 Aug;49(1):20-26. doi: 10.1016/j.semarthrit.2018.12.006. Epub 2018 Dec 28.

PMID:
30685064
10.

The need for comparative data in spondyloarthritis.

Choy E, Baraliakos X, Behrens F, D'Angelo S, de Vlam K, Kirkham BW, Østergaard M, Schett GA, Rissler M, Chaouche-Teyara K, Perella C.

Arthritis Res Ther. 2019 Jan 22;21(1):32. doi: 10.1186/s13075-019-1812-3.

11.

Quantitative susceptibility mapping detects neovascularization of the epiphyseal cartilage after ischemic injury in a piglet model of legg-calvé-perthes disease.

Johnson CP, Wang L, Tóth F, Aruwajoye O, Kirkham B, Carlson CS, Kim HKW, Ellermann JM.

J Magn Reson Imaging. 2019 Jul;50(1):106-113. doi: 10.1002/jmri.26552. Epub 2018 Dec 17.

PMID:
30556613
12.

IL-17 in the immunopathogenesis of spondyloarthritis.

Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW.

Nat Rev Rheumatol. 2018 Aug;14(8):453-466. doi: 10.1038/s41584-018-0044-2. Review.

PMID:
30006601
13.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

14.

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.

Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B.

Pharmacoeconomics. 2018 Jul;36(7):867-878. doi: 10.1007/s40273-018-0674-x.

15.

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.

Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T, Fakhouri W, Taylor PC.

Rheumatol Int. 2018 Jun;38(6):935-947. doi: 10.1007/s00296-018-4005-5. Epub 2018 Mar 21. Review.

16.

Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535. doi: 10.1002/acr.23537. Epub 2018 Sep 1.

17.

Enthesitis: from pathophysiology to treatment.

Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D.

Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741. doi: 10.1038/nrrheum.2017.188. Review.

PMID:
29158573
18.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

19.

Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic.

Momen SE, Kirkham B, Barker JN, Smith CH.

Br J Dermatol. 2017 Dec;177(6):1519-1526. doi: 10.1111/bjd.15866. Epub 2017 Dec 11. Review. No abstract available.

PMID:
28771665
20.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
21.

Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting.

Krueger JG, Kirkham B, Ritchlin CT.

J Rheumatol. 2017 May;44(5):679-683. doi: 10.3899/jrheum.170143.

PMID:
28461524
22.

A new era for collaboration?

Packham JC, Abraham S, Kirkham B, Helliwell P, Siebert S, Korendowych E, Fitzgerald O, Parkinson A, Brookes M, Coates L, McHugh N.

Rheumatology (Oxford). 2018 May 1;57(5):775-776. doi: 10.1093/rheumatology/kex083. No abstract available.

PMID:
28407115
23.

Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound.

Mian AN, Chaabo K, Wajed J, Subesinghe S, Gullick NJ, Kirkham B, Garrood T.

BMC Musculoskelet Disord. 2016 Sep 23;17(1):404.

24.

Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.

Kirkham B, Chaabo K, Hall C, Garrood T, Mant T, Allen E, Vincent A, Vasconcelos JC, Prevost AT, Panayi GS, Corrigall VM.

Rheumatology (Oxford). 2016 Nov;55(11):1993-2000. Epub 2016 Aug 7.

25.

Identification of hidden health utilization services and costs in adults awaiting tertiary care following mild traumatic brain injury in Toronto, Ontario, Canada.

Hunt C, Zanetti K, Kirkham B, Michalak A, Masanic C, Vaidyanath C, Bhalerao S, Cusimano MD, Baker A, Ouchterlony D.

Concussion. 2016 Aug 8;1(4):CNC21. doi: 10.2217/cnc-2016-0009. eCollection 2016 Dec.

26.

Psoriatic arthritis.

Durham LE, Taams LS, Kirkham BW.

Br J Hosp Med (Lond). 2016 Jul;77(7):C102-8. doi: 10.12968/hmed.2016.77.7.C102. Review. No abstract available.

PMID:
27388392
27.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group.

N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.

28.

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

Durham LE, Kirkham BW, Taams LS.

Curr Rheumatol Rep. 2015 Aug;17(8):55. doi: 10.1007/s11926-015-0529-9. Review.

PMID:
26209291
29.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group.

Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.

PMID:
26135703
30.

Rheumatoid Arthritis - Anti-TNF.

Chaabo K, Kirkham B.

Int Immunopharmacol. 2015 Aug;27(2):180-4. doi: 10.1016/j.intimp.2015.04.051. Epub 2015 May 8. Review.

PMID:
25962818
31.

The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome.

Baer AN, McAdams DeMarco M, Shiboski SC, Lam MY, Challacombe S, Daniels TE, Dong Y, Greenspan JS, Kirkham BW, Lanfranchi HE, Schiødt M, Srinivasan M, Umehara H, Vivino FB, Vollenweider CF, Zhao Y, Criswell LA, Shiboski CH; Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups.

Ann Rheum Dis. 2015 Aug;74(8):1557-61. doi: 10.1136/annrheumdis-2014-206683. Epub 2015 Mar 3.

32.

Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.

Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, Tarallo M.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11-9. Epub 2014 Dec 22.

PMID:
25535650
33.

TNF-α blockade induces IL-10 expression in human CD4+ T cells.

Evans HG, Roostalu U, Walter GJ, Gullick NJ, Frederiksen KS, Roberts CA, Sumner J, Baeten DL, Gerwien JG, Cope AP, Geissmann F, Kirkham BW, Taams LS.

Nat Commun. 2014;5:3199. doi: 10.1038/ncomms4199.

34.

Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools.

Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1410-6. doi: 10.1002/acr.22284.

35.

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression.

Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, Taams LS, Kirkham BW.

Arthritis Rheumatol. 2014 May;66(5):1272-81. doi: 10.1002/art.38376.

36.

Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors.

Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Br J Dermatol. 2014 Apr;170(4):995-6. doi: 10.1111/bjd.12824. No abstract available.

PMID:
24400977
37.

Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.

Wasko MC, Hsia EC, Kirkham B, Touboul PJ, Fleischmann R, Genovese MC, Matteson EL, Lu J, Xu W, Rahman MU.

J Clin Rheumatol. 2014 Jan;20(1):1-10. doi: 10.1097/RHU.0000000000000053.

PMID:
24356481
38.

Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice.

Wajed J, Helliwell P, Korendowych E, Gadsby K, Oliver S, Parrish L, Kirkham B.

Ann Rheum Dis. 2014 Jan;73(1):318-9. doi: 10.1136/annrheumdis-2013-203798. Epub 2013 Aug 30. No abstract available.

PMID:
23994863
39.

Pure hydroxyapatite phantoms for the calibration of in vivo X-ray fluorescence systems of bone lead and strontium quantification.

Da Silva E, Kirkham B, Heyd DV, Pejović-Milić A.

Anal Chem. 2013 Oct 1;85(19):9189-95. doi: 10.1021/ac401877d. Epub 2013 Sep 16.

PMID:
23980923
40.

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.

Kirkham BW, Kavanaugh A, Reich K.

Immunology. 2014 Feb;141(2):133-42. doi: 10.1111/imm.12142. Review.

41.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
42.

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study).

Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Br J Dermatol. 2013 Apr;168(4):802-7. doi: 10.1111/bjd.12190. Erratum in: Br J Dermatol. 2013 Jun;168(6):1376. Burden-The, E [corrected to Burden-Teh, Esther].

PMID:
23311587
43.

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.

Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU.

Ann Rheum Dis. 2014 Jan;73(1):161-9. doi: 10.1136/annrheumdis-2012-202089. Epub 2013 Jan 7.

44.

Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.

Walter GJ, Evans HG, Menon B, Gullick NJ, Kirkham BW, Cope AP, Geissmann F, Taams LS.

Arthritis Rheum. 2013 Mar;65(3):627-38. doi: 10.1002/art.37832.

45.
46.

American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T; Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups.

Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87.

47.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036. No abstract available.

PMID:
22460137
48.

Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry.

Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R, Dong Y, Helin P, Kirkham BW, Li M, Sugai S, Umehara H, Vivino FB, Vollenweider CF, Zhang W, Zhao Y, Greenspan JS, Daniels TE, Criswell LA.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):911-8. doi: 10.1002/acr.21610. Epub 2012 Jan 11.

49.

Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years.

Gullick NJ, Oakley SP, Zain A, Gibson T, Jones T, Mistlin A, Rees JD, Panayi GS, Kirkham BW.

Rheumatology (Oxford). 2012 Apr;51(4):759-61. doi: 10.1093/rheumatology/ker399. Epub 2012 Jan 5. No abstract available.

50.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. No abstract available.

PMID:
21339216

Supplemental Content

Loading ...
Support Center